Sridhar K Rabindran
Overview
Explore the profile of Sridhar K Rabindran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2357
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hellmann M, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S, Carcereny Costa E, et al.
N Engl J Med
. 2019 Sep;
381(21):2020-2031.
PMID: 31562796
Background: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with...
2.
Dumble M, Crouthamel M, Zhang S, Schaber M, Levy D, Robell K, et al.
PLoS One
. 2014 Jul;
9(6):e100880.
PMID: 24978597
Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of malignancies. GSK2110183 and GSK2141795 are orally bioavailable, potent...
3.
Medina J, Becker C, Blackledge C, Duquenne C, Feng Y, Grant S, et al.
J Med Chem
. 2011 Feb;
54(6):1871-95.
PMID: 21341675
Phosphoinositide-dependent protein kinase-1(PDK1) is a master regulator of the AGC family of kinases and an integral component of the PI3K/AKT/mTOR pathway. As this pathway is among the most commonly deregulated...
4.
Sabbatini P, Korenchuk S, Rowand J, Groy A, Liu Q, Leperi D, et al.
Mol Cancer Ther
. 2009 Oct;
8(10):2811-20.
PMID: 19825801
The insulin-like growth factor-I receptor (IGF-IR) signaling pathway is activated in various tumors, and inhibition of IGF-IR kinase provides a therapeutic opportunity in these patients. GSK1838705A is a small-molecule kinase...
5.
Sabbatini P, Rowand J, Groy A, Korenchuk S, Liu Q, Atkins C, et al.
Clin Cancer Res
. 2009 Apr;
15(9):3058-67.
PMID: 19383820
Purpose: Dysregulation of the insulin-like growth factor-I receptor (IGF-IR) signaling pathway has been implicated in the development of many types of tumors, including prostate, colon, breast, pancreatic, ovarian, and sarcomas....
6.
Tsou H, Liu X, Birnberg G, Kaplan J, Otteng M, Tran T, et al.
J Med Chem
. 2009 Mar;
52(8):2289-310.
PMID: 19317452
The series of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-dione and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-dione derivatives reported here represents a novel class of potential antitumor agents, which potently and selectively inhibit CDK4 over CDK2 and CDK1. In the benzylamino...
7.
Wang Y, Honores E, Wu B, Johnson S, Powell D, Miranda M, et al.
Bioorg Med Chem
. 2009 Feb;
17(5):2091-100.
PMID: 19200741
Checkpoint deficiency of malignant cells can be exploited in cancer drug discovery. Compounds that selectively kill checkpoint-deficient cells versus checkpoint-proficient cells can be utilized to preferentially target tumor cells, while...
8.
Tsou H, Otteng M, Tran T, Floyd Jr M, Reich M, Birnberg G, et al.
J Med Chem
. 2008 May;
51(12):3507-25.
PMID: 18494457
The cyclin-dependent kinases (CDKs), as complexes with their respective partners, the cyclins, are critical regulators of cell cycle progression. Because aberrant regulations of CDK4/cyclin D1 lead to uncontrolled cell proliferation,...
9.
Powell D, Gopalsamy A, Wang Y, Zhang N, Miranda M, McGinnis J, et al.
Bioorg Med Chem Lett
. 2007 Feb;
17(6):1641-5.
PMID: 17275298
A novel series of antiproliferative agents containing pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides, selective for p21-deficient cells, were identified by high-throughput screening. Exploration of the SAR relationships in the headpiece, core, and tailpiece...
10.
Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, et al.
Proc Natl Acad Sci U S A
. 2006 May;
103(20):7817-22.
PMID: 16672372
The tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) have shown anti-tumor activity in the treatment of non-small cell lung cancer (NSCLC). Dramatic and durable responses have occurred in NSCLC...